Trial
NCT04465760
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OHSU Knight Cancer Institute
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science University
Condition
Lymphoma
Intervention
Xisomab 3G3
Why stopped
Insufficient accrual rate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-24